NCT02525757

MPDL3280A With Chemoradiation for Lung Cancer

Active, enrolled Phase 2 Last updated 4 February 2026

What this trial tests

Phase 2 trial testing MPDL3280A in Lung Cancer in 52 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

26 January 2016

Primary endpoint
31 January 2028

31 January 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	26 January 2016
Primary completion	31 January 2028
Estimated completion	31 January 2028
Sites	1 location across United States

Drugs / interventions tested

• MPDL3280A — full drug profile →
• Carboplatin (Carboplatin) — full drug profile →
• Paclitaxel — full drug profile →
• Radiation Therapy — full drug profile →

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →
• Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn about the safety of adding MDPL3280A to standard chemotherapy (a combination of carboplatin and paclitaxel) and radiation in patients with lung cancer.

You are being asked to take part in this study because you have non-small cell lung cancer (NSCLC) that is unresectable (cannot be removed by surgery) and has not spread.

This is an investigational study. MPDL3280A is not FDA approved or commercially available. It is currently being used for research purposes only. Paclitaxel, carboplatin, and the radiation therapy are all FDA approved for the treatment of lung cancer. The use of these drugs in combination is considered investigational.

Up to 40 participants will be enrolled in this study. All will take part at MD Anderson.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
   Moding EJ, Liu Y, Nabet BY, Chabon JJ, et al · · 2020 · cited 278× · PMID 34505064 · DOI 10.1038/s43018-019-0011-0
2. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.
   Wang Y, Deng W, Li N, Neri S, et al · · 2018 · cited 258× · PMID 29556198 · DOI 10.3389/fphar.2018.00185
3. Tumor-associated macrophages: an effective player of the tumor microenvironment.
   Basak U, Sarkar T, Mukherjee S, Chakraborty S, et al · · 2023 · cited 212× · PMID 38035101 · DOI 10.3389/fimmu.2023.1295257
4. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
   Zhou F, Qiao M, Zhou C. · · 2021 · cited 177× · PMID 33177696 · DOI 10.1038/s41423-020-00577-5
5. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.
   Spiotto M, Fu YX, Weichselbaum RR. · · 2016 · cited 177× · PMID 28018989 · DOI 10.1126/sciimmunol.aag1266
6. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy.
   Shevtsov M, Sato H, Multhoff G, Shibata A. · · 2019 · cited 137× · PMID 30941308 · DOI 10.3389/fonc.2019.00156
7. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.
   Lee JB, Kim HR, Ha SJ. · · 2022 · cited 124× · PMID 35291660 · DOI 10.4110/in.2022.22.e2
8. Current and Future Clinical Applications of ctDNA in Immuno-Oncology.
   Stadler JC, Belloum Y, Deitert B, Sementsov M, et al · · 2022 · cited 123× · PMID 34815256 · DOI 10.1158/0008-5472.can-21-1718